Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer. Patients who received the drug, Adcetris, immediately after a stem cell transplant, lived significantly longer without the disease progressing than those who were given a placebo, the companies said in a joint statement.